Acknowledging she was genetically predisposed to cancer, Kelly Osbourne said, “Apple doesn’t fall too far from the tree.” ...

June 7, 2024 — A team of researchers has developed a wirelessly activated device that mimics the wavelike muscular function in the esophagus and small intestine ... Engineering Cancer's End ...

There’s no time like the present to tackle an endeavor that you’ve been postponing until the “right” moment came along. With the responsive moon grooving through your sign, you feel like ...

The form will remain open until noon on June 12, when, Sztajn wrote, the collected questions will be submitted to university ...

Germline variations did not predict the risk of taxane-induced peripheral neuropathy (TIPN) in a phase II trial involving ...

Denise (Dee) Casapulla, 54, knows just how much work it takes to keep a household running. Whether it’s staying on top of tasks such as cleaning and grocery shopping, overseeing the kids ...

In the HERCULES trial, pembrolizumab with platinum-based therapy showed promising safety and efficacy in the treatment of ...

An analysis that overviewed dermatologic mobile apps with artificial intelligence (AI) features led researchers to voice ...

In part 2 of our 3-part series, antibody-drug conjugates like enfortumab vedotin and tisotumab vedotin offer novel options ...

An eGFR cutoff of 75 mL/min/1.73 m2 after 1 year of treatment was predictive of progression to chronic kidney disease among patients with lupus nephritis.

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent ...

Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid ...